Giuseppe Ciaramella sold $1.3M of BEAM
President at Beam Therapeutics Inc.. 51,110 shares at an average of $26.27, traded Oct 14, 2024, filed Oct 16, 2024.
Score components
- +20RolePresident
- +25Trade size$1.3M at market
- +5Share of holdings soldSold 24% of holdings
- 0ClusterNo other insider selling within 14 days
- -15Exercise and sellShares came from an option exercise in the same filing
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
This signal so far: 1m -9.9%, 3m -12.4%, 6m -37.7%.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-24-115031, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 14, 2024 | MOption exercise Common Stock10b5-1 | +27,318 | $0.67 | $18k | 196,934 | Oct 16, 2024 |
| Oct 14, 2024 | MOption exercise Common Stock10b5-1 | +12,979 | $4.22 | $55k | 209,913 | Oct 16, 2024 |
| Oct 14, 2024 | MOption exercise Common Stock10b5-1 | +1,457 | $7.22 | $11k | 211,370 | Oct 16, 2024 |
| Oct 14, 2024 | SOpen-market sale Common Stock10b5-1 | -51,110 | $26.27 | $1.3M | 160,260 | Oct 16, 2024 |
| Oct 14, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -27,318 | $0.00 | $0 | 0 | Oct 16, 2024 |
| Oct 14, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -12,979 | $0.00 | $0 | 0 | Oct 16, 2024 |
| Oct 14, 2024 | MOption exercise Stock Option (Right to Buy)derivative10b5-1 | -1,457 | $0.00 | $0 | 0 | Oct 16, 2024 |
Related signals
Other insiders at Beam Therapeutics Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 2Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $4,565 187 shares | -0% | |
| 15Weak | Beam Therapeutics Inc. | Giuseppe Ciaramella President | $1.1M 35,000 shares | -16% | |
| 30Weak | Beam Therapeutics Inc. | John M. Evans CEO | $1.4M 50,000 shares | -5% | |
| 16Weak | Beam Therapeutics Inc. | Christine Bellon Chief Legal Officer | $47k 1,371 shares | -1% | |
| 34Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $217k 6,198 shares | -15% | |
| 26Weak | Beam Therapeutics Inc. | Bethany J Cavanagh SVP, Finance and Treasurer | $91k 3,034 shares | -7% | |
| 35Weak | Beam Therapeutics Inc. | Christine Bellon Chief Legal Officer | $645k 18,629 shares | -16% | |
| 9Weak | Beam Therapeutics Inc. | Christine Bellon Chief Legal Officer | $34k 1,254 shares | -1% | |
| 21Weak | Beam Therapeutics Inc. | Sravan Kumar Emany Chief Financial Officer | $171k 6,294 shares | -8% | |
| 32Weak | BEAMsell Beam Therapeutics Inc. | Fmr LLC owner, other | $12k 459 shares | -97% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.